Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Multiple system atrophy

Part of Movement Disorders

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for multiple system atrophy

13 trials tracked for multiple system atrophy: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 126 citations.

13Trials tracked

3Phase 3 & 4

0Recruiting

2With published results

Phase distribution

Phase 3 3 Phase 2 6 Other / NA 4

Phase 3 Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach Completed · 126 cited
Phase 3 Study of BHV-3241 in Participants With Multiple System Atrophy Completed · 87 cited
Phase 3 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed
Phase 2 Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins Completed
Phase 2 Safinamide for Multiple System Atrophy (MSA) Completed
Phase 2 A Study of TAK-341 in Treatment of Multiple System Atrophy Completed

Show 7 more trials

Phase 2 Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Completed
Phase 2 Exenatide Once-weekly as a Treatment for Multiple System Atrophy Completed
Phase 2 Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin. Completed
N/A Local Heat Stress in Autonomic Failure Patients With Supine Hypertension Completed
N/A Nebivolol in the Supine Hypertension of Autonomic Failure Completed
N/A In-Home Care for Patients With PSP and Related Disorders Completed
N/A Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Multiple system atrophy: what the trials found

New clinical evidence indicates that several pharmacological interventions for multiple system atrophy have failed to produce statistically significant improvements in primary motor or autonomic scales. Specifically, Verdiperstat did not significantly change Modified UMSARS scores at week 48 ³, and EGCG showed no significant impact on the UMSARS-ME score or total UMSARS score ².

Additionally, Droxidopa was found to have no statistically significant effect on orthostatic hypotension measures, including the OHQ, OHDAS, or OHSA composite scores ⁴. Placebo studies also showed no significant changes in UMSARS components ¹ or nocturnal blood pressure and orthostatic tolerance ¹³.

Recent results — preliminary, needs further review

* Intravenous immunoglobulin (IVIg) showed a statistically significant preliminary efficacy for MSA treatment (p=0.0128) ⁸. * Anodal cerebellar and cathodal spinal tDCS resulted in statistically significant changes in ICARS, SARA, and 9HPT scores (p<0.001) ¹².

For the clinician treating this condition

Current evidence suggests that Verdiperstat, EGCG, and Droxidopa do not significantly improve motor or orthostatic symptoms as measured by UMSARS and OHQ scales.
While several pharmacological agents failed to meet primary endpoints, non-pharmacological interventions like tDCS showed statistically significant improvements in ataxia and gait measures.

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.